The upheaval over the FDA's accelerated approval of Biogen's now-pulled Alzheimer's drug Aduhelm in 2021 led HHS' Office of Inspector General to review 24 other accelerated approvals to see if there were similar deficiencies. Sarepta' ...
↧
